Claims
- 1. An isolated antibody that specifically binds to a GDF-8 protein, wherein the GDF-8 protein comprises the amino acid sequence Asp-Glu-His-Xaa-Thr (SEQ ID NO:2), wherein Xaa is Ala, Gly, His, Met, Asn, Arg, Ser, Thr, or Trp, and wherein the antibody reduces one or more biological activities associated with the GDF-8 protein, relative to a GDF-8 protein that is not bound by the same antibody.
- 2. The antibody of claim 1, wherein the antibody binds to the region from amino acid 1 to amino acid 50 of the GDF-8 protein sequence.
- 3. The antibody of claim 1, wherein the antibody binds to the region from amino acid 1 to amino acid 25 of the GDF-8 protein sequence.
- 4. The antibody of claim 1, wherein the antibody binds the amino acid sequence Asp-Phe-Gly-Leu-Asp-Cys-Asp-Glu-His-Xaa-Thr-Glu-Ser-Arg-Cys (SEQ ID NO:5) in the GDF-8 protein, where Xaa is Ala, Gly, His, Met, Asn, Arg, Ser, Thr, or Trp.
- 5. The antibody of claim 1, wherein the antibody binds the amino acid sequence Asp-Phe-Gly-Leu-Asp-Cys-Asp-Glu-His-Ser-Thr-Glu-Ser-Arg-Cys (SEQ ID NO:8) in a GDF-8 protein.
- 6. The antibody of claim 1, wherein the antibody binds the amino acid sequence Asp-Glu-His-Ser-Thr (SEQ ID NO:3) in the GDF-8 protein.
- 7. The antibody of claim 1, wherein the GDF-8 protein comprises an amino acid sequence that is at least 75% identical to SEQ ID NO:15.
- 8. The antibody of claim 7, wherein the GDF-8 protein is SEQ ID NO:15.
- 9. The antibody of claim 1, wherein the antibody recognizes the GDF-8 latent complex, GDF-8 in complex with follisatin, or GDF-8 in complex with a follistatin related protein.
- 10. The antibody of claim 1, wherein the antibody is a monoclonal antibody.
- 11. The antibody of claim 10, wherein the antibody is the JA-16 monoclonal antibody produced by a cell having ATCC Deposit Designation Number PTA-4236.
- 12. A cell that produces the monoclonal antibody of claim 10.
- 13. A pharmaceutical composition comprising the antibody of claim 1.
- 14. The composition of claim 13, further comprising a pharmaceutically acceptable excipient.
- 15. A method of treating a patient suffering from a medical disorder, wherein the patient would therapeutically benefit from an increase in mass of muscle tissue, comprising: administering to a mammal a therapeutically effective dose of an antibody that is capable of specifically binding to a GDF-8 protein, wherein the GDF-8 protein comprises the amino acid sequence Asp-Glu-His-Xaa-Thr (SEQ ID NO:2), wherein Xaa is Ala, Gly, His, Met, Asn, Arg, Ser, Thr, or Trp, and wherein the antibody reduces one or more biological activities associated with a GDF-8 protein in the patient, relative to a patient not receiving the same antibody.
- 16. The method of claim 15, wherein the antibody binds to the GDF-8 protein in the region from amino acid 1 to amino acid 50 of the GDF-8 protein sequence.
- 17. The method of claim 15, wherein the antibody binds to the GDF-8 protein in the region from amino acid 1 to amino acid 25 of the GDF-8 protein sequence.
- 18. The method of claim 15, wherein the antibody binds the amino acid sequence Asp-Phe-Gly-Leu-Asp-Cys-Asp-Glu-His-Xaa-Thr-Glu-Ser-Arg-Cys (SEQ ID NO:5) in the GDF-8 protein, where Xaa is Ala, Gly, His, Met, Asn, Arg, Ser, Thr, or Trp.
- 19. The method of claim 15, wherein the antibody binds the amino acid sequence Asp-Phe-Gly-Leu-Asp-Cys-Asp-Glu-His-Ser-Thr-Glu-Ser-Arg-Cys (SEQ ID NO:8) in a GDF-8 protein.
- 20. The method of claim 15, wherein the antibody binds the amino acid sequence Asp-Glu-His-Ser-Thr (SEQ ID NO:3) in the GDF-8 protein.
- 21. The method of claim 15, wherein the GDF-8 protein comprises an amino acid sequence that is at least 75% identical to SEQ ID NO:15.
- 22. The method of claim 15, wherein the GDF-8 protein is SEQ ID NO:15.
- 23. The method of claim 15, wherein the antibody recognizes the GDF-8 latent complex, GDF-8 in complex with follisatin, or GDF-8 in complex with a follistatin related protein.
- 24. The method of claim 15, wherein the antibody is the JA-16 monoclonal antibody produced by a cell having ATCC Deposit Designation Number PTA-4236.
- 25. The method of claim 15, wherein the medical disorder is a muscular disorder, neuromuscular disorder, adipose tissue disorder, diabetes, or bone degenerative disorder.
- 26. The method of claim 15, wherein the medical disorder is a muscular or neuromuscular disorder.
- 27. The method of claim 15, wherein the medical disorder is muscular dystrophy, muscle atrophy, congestive obstructive pulmonary disease, muscle wasting syndrome, sarcopenia, or cachexia.
- 28. The method of claim 15, wherein the medical disorder is muscular dystrophy.
- 29. The method of claim 15, wherein the medical disorder is obesity, type 2 diabetes, or osteoporosis.
- 30. A cell that produces the monoclonal antibody of claim 1.
- 31. A nucleic acid encoding the antibody of claim 1.
- 32. A diagnostic kit comprising the antibody of claim 1.
- 33. An antibody produced by the cell having ATCC Deposit Designation Number PTA-4236.
- 34. An antibody comprising a heavy chain variable region that comprises an amino acid sequence at least 85% identical to SEQ ID NO:1.
- 35. The antibody of claim 34, wherein the amino acid sequence is SEQ ID NO:1.
- 36. A nucleic acid encoding a heavy chain variable region that comprises an amino acid sequence at least 85% identical to SEQ ID NO:1.
- 37. The nucleic acid of claim 36, wherein the nucleic acid molecule comprises SEQ ID NO:6.
- 38. An isolated antibody that specifically binds to a protein comprising an amino acid sequence as set out in SEQ ID NO:2.
- 39. The antibody of claim 38, wherein the antibody specifically binds to a protein comprising an amino acid sequence as set out in SEQ ID NO:3.
- 40. The antibody of claim 38, wherein the antibody specifically binds to a protein comprising an amino acid sequence as set out in SEQ ID NO:5.
- 41. The antibody of claim 40, wherein the antibody specifically binds to a protein comprising an amino acid sequence as set out in SEQ ID NO:18.
- 42. The antibody of claim 38, which is made using cell line with ATCC Deposit Designation Number PTA-4236.
- 43. The antibody of claim 38, comprising at least one single chain CDR chosen from the amino acids 30-35 of SEQ ID NO:1, amino acids 50-66 of SEQ ID NO:1, and amino acids 99-102 of SEQ ID NO:1.
- 44. A method of increasing muscle mass, said method comprising administering a therapeutically effective amount of the antibody of claim 38 to a mammal, thereby increasing muscle mass.
- 45. A method of increasing trabecular bone density, said method comprising a administering a therapeutically effective amount of the antibody of claim 38 to a mammal, thereby increasing trabecular bone density.
- 46. A method of increasing muscle strength, said method comprising administering a therapeutically effective amount of the antibody of claim 38 to a mammal, thereby increasing muscle strength.
- 47. A nucleic acid encoding antibody of claim 38.
- 48. A method of inhibiting GDF-8 activity comprising providing the antibody of claim 1 and allowing it to inhibit GDF-8 activity.
- 49. An isolated antibody that specifically binds to a protein, wherein the protein comprises the amino acid sequence of SEQ ID NO:9.
- 50. The antibody of claim 49, wherein the protein is BMP-11 or a fragment thereof.
- 51. The antibody of claim 49, which is made using cell line with ATCC Deposit Designation Number PTA-4236.
- 52. A method of increasing muscle mass, said method comprising administering a therapeutically effective amount of the antibody of claim 49 to a mammal, thereby increasing muscle mass.
- 53. A method of increasing trabecular bone density, said method comprising a administering a therapeutically effective amount of the antibody of claim 49 to a mammal, thereby increasing trabecular bone density.
- 54. A method of increasing muscle strength, said method comprising administering a therapeutically effective amount of the antibody of claim 49 to a mammal, thereby increasing muscle strength.
Parent Case Info
[0001] This application claims priority to U.S. provisional patent application Serial No. 60/324,528, filed on Sep. 26, 2001.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60324528 |
Sep 2001 |
US |